Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

al product for the treatment of allergy symptoms

2008 Financial Outlook

-- We expect our net revenue for 2008 will be approximately $75 to $82

million.

-- We expect our gross margin for 2008 will be approximately 70% to 73%,

subject to quarterly fluctuations based on revenue mix.

-- Depending upon the progress of our clinical and pre-clinical programs,

we expect our research and development expenses in 2008 will be

approximately $34 to $38 million, including stock-based compensation

expense, which we estimate will be approximately $1.5 to $2 million.

-- We anticipate our selling, general, and administrative expenses for

2008 will be approximately $50 to $54 million, including stock-based

compensation expense, which we estimate will be approximately $2.5 to

$3.5 million.

Conference Call

ISTA will host a conference call with a simultaneous webcast today, March 6, 2008, at 5:00 PM Eastern Time, to discuss its fourth quarter and full-year 2007 results. To access the live conference call, U.S. and Canadian participants may dial 866-831-6270; international participants may dial 617-213-8858. The access code for the live call is 99457780. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the call is 57762235. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/16/2014)... BCC Research reveals in its ... , the global market for stem cells is expected ... a five-year compound annual growth rate (CAGR) of 13.6%. ... with growth projections of $2.2 billion in 2014 to ... , Unlike other potential applications of bioscience, ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... EDMONTON, June 2 /PRNewswire-FirstCall/ - Quest PharmaTech ... that its 12-patient,Phase I clinical study entitled "ACP-SL017 ... Therapy of Actinic Keratosis" has met both its ... have received, for the first time, clinical,validation for ...
... 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company ... early,detection of diseases and personalized health management, today ... Company,s first,product, ColonSentry(TM)., Effective May 31, 2008, ... CEO to take on new duties as Chief ...
... genetic mutations that can affect patient response to ... ... DxS Ltd. have,signed an exclusive distribution agreement for the DxS TheraScreen ... when considered with other clinically relevant factors, to aid,doctors in identifying ...
Cached Biology Technology:Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3GeneNews announces management changes to support commercialization of ColonSentry(TM) 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
(Date:9/16/2014)... complex web of interaction between viruses, bacteria, and ... a growing international collaboration between Matthew Sullivan, associate ... Ecology and Evolutionary Biology and Steven Hallam from ... , "Bacteria are drivers of nutrient and ... "As the climate is changing, so are the ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... small number of households could go a long way to ... measured differences in energy demands at the household level, appears ... Dominik Saner and colleagues point out that the energy ... mobility needs accounts for more than 70 percent of emissions ...
... accurately, according to a new study by the late ... in Germany. Their analysis of human melody singing in ... work is published online in Springer,s journal Animal ... one of the most complex and demanding cognitive challenges ...
... Down syndrome, more commonly known as "trisomy 21" is ... population: Alzheimer,s disease, leukemia, or cardiac deficiency. In a ... Faculty of Medicine of the University of Geneva (UNIGE), ... 21, determining the risk of congenital heart disease in ...
Cached Biology News:Songbirds turn on and tune up 2Complex genetic architectures: Some common symptoms of trisomy 21 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Kit Includes: Sufficient library for ... x 10^9 independent sequences, -28 gIII ... DNA sequencing, -96 gIII Sequencing Primer ... Host E. coli strain ER2738, Control ...
... The CHEMICON Re-Blot Western Blot Recycling ... antibodies from Western blots that have ... iodine or other isotopes. It is ... (TMB, DAB, 4-chloronapthol, etc.), as it ...
Biology Products: